Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMCH-E111 intravitreal injection in RLBP1-related inherited retinal dystrophy
ChiCTR2600119045Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2026
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of PUMCH-E111 in Fundus dystrophy (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Incidence rate of treatment-emergent adverse events (AE), Incidence rate of serious adverse events (SAE) and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
PUMCH-E111
03
Conditions
Fundus dystrophy
Beyond the preview
Go deeper on ChiCTR2600119045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119045.